David E. Axelrod, Ph.D. * - Piscataway - Our basic science research is aimed at a better understanding of tumor progression and tumor heterogeneity. Our translational research is aimed at improving the diagnosis and prognosis of human breast cancer by developing analytical techniques for computer-aided image analysis and multivariate statistics.
Beverly E. Barton, Ph.D. - Newark - We are studying the role of IL-6-like cytokines and signal transduction in prostate cancer. Using approaches from immunology, e.g. flow cytometry to measure activated signaling proteins, we have demonstrated the activation of STAT3 in neoplastic but not hyperplastic prostate cells.
Subal C. Bishayee, Ph.D. * - Newark - We are interested in receptor tyrosine kinase-mediated signal transduction and how aberrant expression of these receptors leads to altered signaling in cancer. We are also interested in structure-function relationship of these proteins, particularly after their phosphorylation.
Subhasis, B. Biswas, Ph.D. * - Stratford - Our laboratory is interested in dissecting the mechanisms of DNA replication in prokaryotic and eukaryotic systems with goals of developing novel anti-microbials and anti-proliferation drugs. Email: email@example.com
Kenneth J. Breslauer, Ph.D. * - Piscataway - Characterization of the molecular interactions that control biopolymer structure and stability, drug-binding affinity and specificity, relating biophysical properties to biological function, correlating structure and energetics.
Gary Brewer, Ph.D. * - Piscataway - Identification and analyses of cis- and trans-acting factors controlling mRNA decay in cancer, heart disease and immune responses.
Salvatore J. Caradonna, Ph.D. * - Stratford - My laboratory is interested in the post-translational mechanisms that regulate proteins involved in base-excision repair of DNA. We are studying the aberrant pathways that lead to uracil misincorporation into DNA and strategies that may exploit these pathways for cancer drug development. We are also involved in the study of atypical cyclin-like proteins that affect cell-cycle phase transitions. Email: firstname.lastname@example.org
Kiran Chada, Ph.D. * - Piscataway - Mammalian genetics developmental biology, functional genomics, transgenic mice, human diseases, cancer and obesity.
Katrina Cooper, Ph.D * - Stratford - Following stress cells have to orchestrate a myriad of responses to survive or die. Incorrect choices can lead to deleterious outcomes, e.g. tumor formation. To study this, we use S. cerevisiae, human cells and mouse models. We focus on the conserved cyclin C protein that is destroyed in response to stress and plays a role in apoptosis. Our working hypothesis is that cyclin C is a novel stress related tumor suppressor. Email: email@example.com
Scott R. Diehl, Ph.D. * - Newark - Single Nucleotide Polymorphisms (SNPs) are analyzed to understand molecular causes of disease and individual differences in drug responses. High-throughput bioinformatics and complex statistical genetic methods are used for current research on oral cancer, periodontal disease, orofacial clefting; pharmacogenomics of pain and drug responses.
Patricia Fitzgerald-Bocarsly, Ph.D. * - Newark - Studies on the inate immune response to viral infection are focused on a dendritic cell subpopulation (DC2) that produces interferon-alpha in response to viral stimulation. Mechanisms of viral induction of IFN in these cells and their interactions with natural killer cells, and T helper cells are under investigation.
Ramsey A. Foty, Ph.D. * - Piscataway - Our Laboratory studies the biophysical and molecular determinants of prostate cancer invasion and metastasis.
Jonathan Foulds, Ph.D. - Piscataway - Tobacco addiction, smoking cessation, health effects of tobacco, tobacco dependence treatment, psychological and behavioural effects of nicotine and nicotine withdrawal.
Abram Gabriel, M.D. * - Piscataway - My laboratory focuses on the study of mechanisms and consequences of retrotransposon reverse transcription.
Marc R Gartenberg, Ph.D. * - Piscataway - Large regions of eukaryotic chromosomes are heritably maintained in transcriptionally inactive states by repressive chromatin structures. Inappropriate expression of down-regulated genes can lead to cancers and other genetic diseases. We use budding yeast as a model to study how transcriptionally inactive domains are established, maintained, and propagated.
Celine Gelinas, Ph.D. * - Piscataway - The Rel/NF-kB transcription factors play fundamental roles in immune and inflammatory responses, and are implicated in many human hematopoietic and solid cancers. Our research aims at understanding their effects on cellular gene expression, cell growth control, apoptosis and oncogenesis.
Gary, S. Goldberg, Ph.D. - Stratford - Cells must communicate with each other to coordinate the development and survival of an animal. This communication can be mediated by diffusible factors that pass between cells, or by direct contact through cell junctions. I am interested in how intercellular communication affects cell growth and differentiation, with an emphasis on how cell communication can control tumor cell growth and prevent eye diseases. Email: firstname.lastname@example.org
William, N. Hait, M.D., Ph.D. * - Piscataway - Identification of genetic determinants of drug sensitivity in cancer; new targets, signal transduction pathways; oncogenes; translation into genomics based clinical trials.
Utz Herbig, Ph.D * - Newark - Our laboratory is interested in understanding how telomeres contribute cellular senescence in mammalian cells. As cellular senescence is a critical tumor suppressing mechanism, but also is thought to contribute to organismal aging, our studies are relevant for both aging- and cancer-research.
Helene Z. Hill, Ph.D. * - Newark - The bystander effect involves translocation of a death signal between irradiated cells and unexposed neighboring cells. We measure and analyze mutations in these neighboring cells, as well as quantitating DNA damage using the comet assay. Radioisotopes.
Hristo Houbaviy, Ph.D. * - Stratford - We are interested in the roles of microRNAs in embryonic stem (ES) cells and during the early development of the mouse. Specifically, we are applying biochemical and mouse model approaches to elucidate the functions of miR-290-295 / miR-371-373 which appear to be ES cell and early embryo specific. Email: email@example.com
Lisa Huang, Ph.D. * - Stratford - My current research focuses on the identification of cancer biomarkers in the diagnosis and monitoring of cervical cancer, bladder cancer, and prostate cancer. Another of my research focuses on studying the mechanisms of DNA repair and drug resistance in bladder cancer and prostate cancer. These researches aid to assist in novel drug discovery. Email: firstname.lastname@example.org
Neerja Kaushik-Basu, Ph.D. * - Newark - My lab is studying the molecular mechanisms of Hepatitis C Virus Replication and Pathogenesis with specific reference to its non-structural protein NS5B and its RNA. In addition, we are studying the structure-function inter-relation of the SARS virus replicase.
John, E. Kerrigan, Ph.D. * - Piscataway - Our research efforts are aimed toward the identification of novel small molecule therapetics for the treatment of cancer and other diseases using de novo computational methods. Molecular modeling of protein and dna complexes with potential drug leads is applied.
Muriel W. Lambert, Ph.D. * - Newark - Research is ongoing on DNA repair mechanisms, in particular in cells from patients with genetic diseases with repair defects. The genes and proteins involved are being studied as is the interaction of these proteins with damaged DNA and damaged chromatin.
Jerome A. Langer, Ph.D. * - Piscataway - Our interests include how diverse Type I interferons are differentially recognized by a common cell surface receptor and sometimes initiate different cellular responses. We are also examining cellular responses to flaviviruses, particularly dengue virus.
Edmund C. Lattime, Ph.D. * - Piscataway - Our laboratory studies tumor immunology and immunologically based gene therapy based on modulating immune mechanisms active at the tumor-host interface. We study immune mechanisms in both murine and human systems. Clinical trials focus on genetically based vaccine strategies.
Michael Law, Ph.D. * - Stratford - Using S. cerevisiae as a model system, my work is aimed at determining how cell fate decisions are established. Differentiation requires temporal restrictions on transcription to be maintained. My work is interested in defining how post-translational protein modifications allow epigenetic regulation of transcriptional timing. Email: email@example.com
Deborah, A. Lazzarino, Ph.D. * - Newark - Research studies in stem cell biology of the mammary gland in both normal and oncogenic development.
Michael A. Lea, Ph.D. * - Newark - Regulation of cancer cell growth and differentiation is being studied with particular focus on the action of agents that modify histone acetylation.
Chee-Gun Lee, Ph.D * - Newark - The role of RNA helicase A (RHA) in transcription. Functioning as both DNA and RNA helicase, the RHA is also able to associate with dsDNA and nucleosome without any significant difference. Our findings implicate RHA in the development and/or progress of prostate cancer as a factor important for a crosstalk between STAT- and AR-mediated transcription pathways.
S. Joseph Leibovich, Ph.D. * - Newark - Role of macrophages, nitric oxide and oxygen in regulation of angiogenesis in wound healing and cancer. Analysis of VEGF expression in macrophages and its regulation by nitric oxide. Role of ADP-ribosylation of VEGF in macrophages and its role in regulation of angiogenesis.
Michael J. Leibowitz, Ph.D. * - Piscataway - Study of therapeutic agents acting on RNA targets to inhibit Tat-mediated transactivation in HIV-1 and group I intron ribozymes of fungi; epigenetic regulation of viral gene expression; polymeric drug delivery systems. Antibiotics.
Honghua L. Li, Ph.D. * - Piscataway - (1)Genome-scale understanding genetic basis of breast cancer by microdissecting individual invasive carcinoma components and accompanying proliferative lesions and by multiplex genotype analysis; and (2) understanding the mechanisms underlying human immunoglobulin VH gene complex diversification.
Leroy F. Liu, Ph.D. * - Piscataway - Roles of topoisomerases mediating genome instability, carcinogenesis and tumor cell death investigated. Three areas are: a) Topoisomerase I a new molecular target for anticancer drugs. b) Repair topoisomerase I-mediated DNA damage. c) Role of topoisomerase II in tumor cell death and carcinogenesis.
David M. Lukac, Ph.D. * - Newark - Molecular virology of Kaposi`s sarcoma-associated herpesvirus (HHV-8) in the pathogenesis of Kaposi`s sarcoma and primary effusion lymphoma.
Carol S. Lutz, Ph.D. * - Newark - We are interested in how eukaryotic gene expression is regulated at the level of mRNA processing, particularly in splicing and polyadenylation. Some of the protein factors involved are autoantigens in patients with lupus, and we are also interested in understanding this phenomenon.
Stuart G. Lutzker, M.D., Ph.D. * - Piscataway - My lab examines the role of the p53 transcription factor in the cellular response to DNA damage. We have developed a unique genetic system to test the role of specific post-translational modifications in fine-tuning the p53 response.
William McAllister, Ph.D * - Stratford - Molecular basis of transcription. Work in our laboratory concerns the structure and function of RNA polymerase, the enzyme that carries out the first step in gene expression, using a combination of biochemical, genetic, and structural methods. Email: firstname.lastname@example.org
Randall D. McKinnon, Ph.D. * - Piscataway - Oligodendrocyte development; transplantation analysis of primary OL progenitor cells engineered to be non-responsive to specific factors using dominant-negative receptor constructs; signal transduction by receptors with intrinsic catalytic protein tyrosine kinase activity; gene expression analysis using microarray chip technology.
Carlos A. Molina, Ph.D. * - Newark - We are interested in the regulation of gene expression during the cell cycle by the tumor suppressor and transcriptional repressor, Inducible cAMP Early Repressor (ICER). Circadian rhythm.
Susan Muller-Weeks, Ph.D. * - Stratford - Research in the laboratory focuses on the repair of uracil in DNA, which is critical for the maintenance of genomic integrity. Specifically we are elucidating transcriptional and post-translational pathways that regulate expression of uracil-DNA glycosylase under normal cellular conditions and in response to anti-tumor agents. Email: email@example.com
Robert Nagele, Ph.D. * - Stratford - My laboratory is focused on elucidating the role of breakdown of the blood-brain barrier in the initiation and progression of Alzheimer`s and other neurodegenerative diseases and developing therapeutic strategies aimed at preventing this breakdown and the leak of potentially damaging blood components into the brain tissue. In addition, my laboratory is investigating the potential of certain blood-borne autoantibodies as biomarkers of disease that can be used for disease diagnostics or a monitor or disease progression. Email: firstname.lastname@example.org
Joseph I. Naus, Ph.D. * - Piscataway - Bioinfomatics, computational molecular biology. Significant multiple matching in DNA and protein sequences, scan statistics, unusual clustering, including temporal and spatial clustering of disease. Data Editing.
Catherine Neary, Ph.D. * - Stratford - Hexokinase II (HK2), which catalyzes the first committed step of glycolysis, is overexpressed in many cancers. When inhibited, HK2 translocates from the mitochondria to the nucleus. I am investigating the signaling pathways that mediate HK2 mitochondrial association and nuclear translocation. Email: email@example.com
Harvey Ozer, M.D. * - Newark - Carcinogenesis and Regulation of Cellular Aging. We have been studying human diploid fibroblasts (HF) and introduction of genes from the DNA tumor virus SV40 to understand the mechanism of multi-step carcinogenesis ("transformation") in culture and its effect on bypassing cellular aging and facilitating immortalization.
John Pastorino, PhD * - Stratford - Our work identifies distinctions in mitochondrial function between normal and cancerous cells for the potential discovery of novel chemotherapeutic targets that can be exploited to selectively induce cytotoxicity in cancer cells. Mitochondrial injury is also central to number of disease states. Email: firstname.lastname@example.org
Sidney Pestka, M.D. * - Piscataway - Research involves the cloning of interferons and their receptors, and the development of new strategies for the treatment of viral diseases and cancers. The studies involve interferon and cell surface receptors and revolve around genetic engineering, protein biochemistry, signal transduction, immunology and gene therapy.
Nicholas M. Ponzio, Ph.D. * - Newark - Use of experimental models to study: (1) development and treatment of B cell lymphomas and leukemias, and (2) transplantation of umbilical cord blood in lieu of bone marrow for treatment of various diseases in which hematopoiesis is compromised.
Arnold B. Rabson, M.D. * - Piscataway - Our laboratory studies the molecular virology of HIV/AIDS and HTLV with a focus on regulation of viral gene expression. A second focus is the role of transcription factors in cancer and oncogenesis, particularly in lymphomas and prostate cancer.
Pranela Rameshwar, * - Newark - Hematopoiesis: homeostasis vs. dysfunction
Lyndi Rice, Ph.D. * - Stratford - The focus of our group is to elucidate the molecular regulation of several tumor suppressors and oncogenes in the onset of gynecological cancers, using cell culture, primary tissues, and mouse model systems. Through our research, we will identify novel biomarkers to aid in early detection and potential drug targets that modulate tumor progression. Email: email@example.com
Melissa B. Rogers, Ph.D. * - Newark - Retinoids control cell cycle, apoptosis, & differentiation. We study how retinoic acid controls key genes like BMP-2. We use enhancer traps to isolate RA response elements. Our functional genomics approach should identify RA-regulated genes that initiate critical signaling cascades in development.
Yufang Shi, Ph.D., D.V.M. * - Piscataway - We are interested in understanding the role of apoptosis in regulating immune responses. The mechanisms controlling FASL, TRAIL, RANKL and TNF expression in T cells are the main focus. We are also studying psychoneuroimmunology, especially the effects of stress and opioids on the immune system.
Ilana Stroke, Ph.D. * - Stratford - We are using high throughput compound screening (HTS) technology to identify small molecules providing the basis for novel drugs modulating microbial infection, cancer, inflammation, metabolic disease, and cardiovascular disease. Email: firstname.lastname@example.org
George P. Studzinski, M.D.,Ph.D. * - Newark - With the objective of advancing cancer chemotherapy options,we are studying the mechanisms of induction of mature monocytic phenotype and cell cycle arrest in human myeloid leukemia cells(HL60,U937,etc).Analogs of vitamin D are principal inducing agents,and MAPK and PI3K pathways are the current focus.
Katsunori Sugimoto, Ph.D. * - Newark - Our research focuses on molecular mechanisms of how cells activate "checkpoint" signaling pathways after DNA damage. Checkpoint defects are associated with cancer-prone genetic disorder ataxia telangiectasia (AT).
Thresia Thomas, Ph.D. * - Piscataway - Development of therapeutics for breast cancer based on polyamines and estrogens. Molecular mechanism(s) of estrogenic function through the estrogen receptor. Transcriptional regulation of gene expression. Role of environemntal estrogens in breast cancer. Estradiol metabolic pathways
Jason Trama, Ph.D. * - Stratford - Our laboratory uses proteomic and genomic data to identify biomarkers for gynecologic and urologic cancers. Our goal is to develop noninvasive methods for diagnosis and monitoring. We also study the mechanisms of tumorigenesis, metastasis and drug resistance in order to identify targets for therapy. Email: email@example.com
Nancy Walworth, Ph.D. * - Piscataway - Studies on cell cycle checkpoints: signal transduction pathways that control cell cycle progression in response to DNA damage or DNA replication blocks, using the genetically tractable fission yeast, Schizosaccharomyces pombe as a model system. Checkpoint defects are apparent in cells of patients with the cancer-prone genetic disorder ataxia telangiectasia (AT).
Ian P. Whitehead , Ph.D. * - Newark - Our laboratory examines mammalian signal transduction and its relationship to cancer. More specifically, we utilize highly efficient, retroviral-based expression systems to identify and characterize oncogenes whose expression contribute to the metastatic potential of human breast tumors.
Nancy, A. Woychik, Ph.D. * - Piscataway - RNA polymerases and transcription regulation in cancer and other diseases; Alterations in host cell transcription upon smallpox virus infection; Transcription mechanisms important for Chlamydia pathogenesis; Chlamydia infection and heart disease.
Lizhao Wu, Ph.D. * - Newark - We use a combination of molecular, cellular, and genetic approaches to identify key molecules that are important for cancer. Both cell culture systems and mouse models are used to delineate various tumor suppressor/oncogenic pathways in the hematopoietic system, prostate gland, and mammary gland.
Chung S. Yang, Ph.D. * - Piscataway - Nutrition, cancer.